426 related articles for article (PubMed ID: 38334807)
1. Exploring the nexus of nuclear receptors in hematological malignancies.
Manickasamy MK; Sajeev A; BharathwajChetty B; Alqahtani MS; Abbas M; Hegde M; Aswani BS; Shakibaei M; Sethi G; Kunnumakkara AB
Cell Mol Life Sci; 2024 Feb; 81(1):78. PubMed ID: 38334807
[TBL] [Abstract][Full Text] [Related]
2. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
3. Acute myeloid leukaemia following direct acting antiviral drugs in HCV-infected patients: A 10 years' retrospective single-center study.
Scheifer C; Luckina E; Lebrun-Vignes B; Diop AA; Damais-Thabut D; Roos-Weil D; Dechartres A; Lebray P
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):102000. PubMed ID: 35933093
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
5. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
Valentin R; Grabow S; Davids MS
Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
[TBL] [Abstract][Full Text] [Related]
6. Deciphering the messages carried by extracellular vesicles in hematological malignancies.
Longjohn MN; Hudson JBJ; Smith NC; Rise ML; Moorehead PC; Christian SL
Blood Rev; 2021 Mar; 46():100734. PubMed ID: 32736879
[TBL] [Abstract][Full Text] [Related]
7. Demystifying the Functional Role of Nuclear Receptors in Esophageal Cancer.
Jayaprakash S; Hegde M; Girisa S; Alqahtani MS; Abbas M; Lee EHC; Yap KC; Sethi G; Kumar AP; Kunnumakkara AB
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142861
[TBL] [Abstract][Full Text] [Related]
8. Nuclear receptors in oral cancer-Emerging players in tumorigenesis.
Gangwar SK; Kumar A; Jose S; Alqahtani MS; Abbas M; Sethi G; Kunnumakkara AB
Cancer Lett; 2022 Jun; 536():215666. PubMed ID: 35364221
[TBL] [Abstract][Full Text] [Related]
9. BH3 Mimetics in Hematologic Malignancies.
Klener P; Sovilj D; Renesova N; Andera L
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576319
[TBL] [Abstract][Full Text] [Related]
10. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
11. Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy.
Yang XJ; Xi YM; Li ZJ
Biomed Res Int; 2019; 2019():4860268. PubMed ID: 31032347
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.
Gur I; Giladi A; Isenberg YN; Neuberger A; Stern A
Acta Haematol; 2022; 145(3):297-309. PubMed ID: 35235928
[TBL] [Abstract][Full Text] [Related]
13. Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia.
Pan P; Chen X
Cells; 2020 Aug; 9(9):. PubMed ID: 32824945
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets.
Ding Z; Shi R; Hu W; Tian L; Sun R; Wu Y; Zhang X
Front Oncol; 2023; 13():1193978. PubMed ID: 37746306
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of controlling nutritional status score in hematological malignancies.
Zhang Y; Chen Q; Lu C; Yu L
Hematology; 2022 Dec; 27(1):653-658. PubMed ID: 35622088
[TBL] [Abstract][Full Text] [Related]
16. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
[TBL] [Abstract][Full Text] [Related]
17. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
18. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
19. A multicenter retrospective study defining the clinical and hematological manifestations of brucellosis and pancytopenia in a large series: Hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis.
Sari I; Altuntas F; Hacioglu S; Kocyigit I; Sevinc A; Sacar S; Deniz K; Alp E; Eser B; Yildiz O; Kaynar L; Unal A; Cetin M
Am J Hematol; 2008 Apr; 83(4):334-9. PubMed ID: 18069671
[TBL] [Abstract][Full Text] [Related]
20. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Yang Z; Wang Y
Chin Med J (Engl); 2023 Oct; 136(19):2285-2296. PubMed ID: 37358555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
